CervoMed Inc. announced that its drug candidate neflamapimod has been granted an Innovation Passport to enter the UK’s Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). This designation, awarded on August 4, 2026, provides early coordination with UK regulators and health technology assessment bodies to potentially accelerate market access. The company is currently seeking a strategic partner to advance neflamapimod into a Phase 3 trial for DLB. CervoMed Inc. operates in the biotechnology industry, developing treatments for age-related brain disorders.
